Prometheus Biosciences Performance
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
The company holds a Beta of -0.42, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Prometheus Biosciences are expected to decrease at a much lower rate. During the bear market, Prometheus Biosciences is likely to outperform the market. Prometheus Biosciences right now holds a risk of 0.0%. Please check Prometheus Biosciences potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Prometheus Biosciences will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Prometheus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Prometheus Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 257.3 M |
Prometheus |
Prometheus Biosciences Relative Risk vs. Return Landscape
If you would invest 19,992 in Prometheus Biosciences on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Prometheus Biosciences or generate 0.0% return on investment over 90 days. Prometheus Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Prometheus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prometheus Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prometheus Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prometheus Biosciences, and traders can use it to determine the average amount a Prometheus Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RXDX |
Based on monthly moving average Prometheus Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prometheus Biosciences by adding Prometheus Biosciences to a well-diversified portfolio.
Prometheus Biosciences Fundamentals Growth
Prometheus Stock prices reflect investors' perceptions of the future prospects and financial health of Prometheus Biosciences, and Prometheus Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prometheus Stock performance.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X | |||
| Price To Sales | 627.82 X | |||
| Revenue | 6.81 M | |||
| EBITDA | (145.78 M) | |||
| Cash And Equivalents | 95.96 M | |||
| Cash Per Share | 2.35 X | |||
| Total Debt | 14.76 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 14.62 X | |||
| Cash Flow From Operations | (123.25 M) | |||
| Earnings Per Share | (3.54) X | |||
| Total Asset | 740.77 M | |||
| Retained Earnings | (331.09 M) | |||
| Current Asset | 135.99 M | |||
| Current Liabilities | 24.54 M | |||
About Prometheus Biosciences Performance
Evaluating Prometheus Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Prometheus Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prometheus Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.Things to note about Prometheus Biosciences performance evaluation
Checking the ongoing alerts about Prometheus Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prometheus Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prometheus Biosciences is not yet fully synchronised with the market data | |
| Prometheus Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M). | |
| Prometheus Biosciences currently holds about 95.96 M in cash with (123.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.35. | |
| Over 81.0% of the company shares are owned by institutional investors |
- Analyzing Prometheus Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prometheus Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Prometheus Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prometheus Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prometheus Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prometheus Biosciences' stock. These opinions can provide insight into Prometheus Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |